Study on the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention
试验速览
- 阶段
- 4 期
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- serum uric acid
研究概览
简要总结
To investigate the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention
详细描述
This study aims to explore the best effective dose and adverse reaction of febuxostat in lowering serum uric acid to low level in patients with Chronic Renal Disease at different stages. To elucidate that low levels of serum uric acid can delay the progression of renal damage. Promote the application of anti uric acid drugs in the treatment of chronic renal failure and delay the progress of CKD in patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Non-dialysis CKD patients with serum uric acid greater than 7mg/dl.
- •eGFR≥15ml/min/1.73m².
- •Low salt, low protein, low purine diet.
排除标准
- •Take drugs that raise blood uric acid at the same time.
- •Patients with gout attacks.
- •Patients with pregnant, lactating.
- •Autosomal dominant polycystic kidney disease.
- •Patients with poor general condition and multiple organ failure.
研究组 & 干预措施
Treatment group1
Febuxostat pill 20mg was used to treat CKD patients with hyperuricaemia.
干预措施: 20mg Febuxostat (Drug)
Treatment group2
Febuxostat pill 40mg was used to treat CKD patients with hyperuricaemia.
干预措施: 40mg Febuxostat (Drug)
结局指标
主要结局
serum uric acid
时间窗: up to 6 months
intravenous blood sampling
次要结局
- serum creatinine(up to 6 months)